Post by Hot Christian Stocks on Apr 1, 2014 12:26:34 GMT -5
Providing continuing
coverage of
Nuvilex,
OTCQB: (NVLX)
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
SILVER SPRING, Md., April 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box® technology.
"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."
The PCRT, an affiliate of TD2, has the explicit mission to organize and accelerate the clinical development of new agents for the treatment of patients with pancreatic cancer. The PCRT members include laboratory and clinical researchers in the U.S. and Western Europe who share the passion to bring new advances to patients with pancreatic cancer as rapidly as possible, providing the only coordinated effort in the world dedicated to rapidly translating research discoveries into new treatments and supportive care for pancreatic cancer patients exclusively. To date, the PCRT consists of approximately 65 Oncology Clinicians, Surgeons and Researchers who are member-investigators of the PCRT and who represent 45 clinical research sites.
In commenting on TD2's work with Nuvilex, Kenneth L. Waggoner, Chief Executive Officer and President of Nuvilex, stated, "We are honored that TD2 and Dr. Von Hoff will play a pivotal role in the development of our treatment for patients with advanced pancreatic cancer that combines the proprietary Cell-in-a-Box® live-cell encapsulation technology with the cancer drug ifosfamide. TD2 integrates world-class preclinical, clinical and regulatory expertise and provides unique drug development services aimed at minimizing the risk for its clients in the oncology drug development industry. In addition, access to the PCRT that is enabled by our association with TD2 will not only make Nuvilex's approach widely known, but should facilitate its development as we move forward. The sincere interest in our advanced pancreatic cancer treatment that has been shown by TD2 is particularly rewarding to all of us."
TD2 is a precision oncology Contract Research Organization (CRO) that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 has managed and conducted more than 60 early-mid phase clinical studies and has worked with more than 350 biotech and pharmaceutical companies worldwide.
TD2 has facilities for the preclinical and clinical testing of candidate cancer drugs and treatments, as well as expertise in regulatory affairs matters with agencies such as the FDA. TD2 has more than 200 established models of human cancers available for preclinical studies and develops comprehensive drug development plans for the most efficient pathway for successful clinical trials. In addition, TD2 has capabilities and expertise in all aspects related to the conduct and management of clinical trials. TD2's drug regulatory affairs capabilities include the preparation and maintenance of Investigational New Drug Applications (INDs) that are necessary prior to the initiation of clinical trials, support for obtaining "breakthrough" designations and "fast track, priority review and accelerated approval" filings for cancer drugs and treatments. The TD2 team has collective experience in filing more than 60 INDs in the U.S. alone. In countries outside the U.S., TD2 can provide filing and maintenance services for Clinical Trial Applications and Investigational Medicinal Product Dossiers.
Read full press release here
Tuesday, April 1, 2014
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic CancerGlobeNewswire( (Tue 9:00AM EDT)
Tuesday, March 25, 2014
Nuvilex to Present at National Medical Cannabis Unity Conference in Washington DCGlobeNewswire( (Tue, Mar 25)
Thursday, March 20, 2014
Nuvilex Contracts With Austrianova for cGMP-Compliant Cell-in-a-Box(R) Encapsulation of Cells for Clinical TrialsGlobeNewswire( (Thu, Mar 20)
Monday, March 17, 2014
Professor Dr. Walter H. Gunzburg, Executive Chairman and Chief Technical Officer of Nuvilex Affiliate SG Austria, Presents at 2014 BioPharma Asia Convention in SingaporeGlobeNewswire( (Mon, Mar 17)
Thursday, March 13, 2014
Cannabis Market News & Volume Leaders Briefing - Company Signs LOI For Washington State Cannabis Retail OutletsPR Newswire( (Thu, Mar 13)
Tuesday, March 11, 2014
Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory BoardGlobeNewswire( (Tue, Mar 11)
Friday, March 7, 2014
Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary's Scientific Advisory BoardGlobeNewswire( (Fri, Mar 7)
Thursday, March 6, 2014
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell EncapsulationGlobeNewswire( (Thu, Mar 6)
Recent Events Effectively De-Risk Nuvilex, Inc.PR Newswire( (Thu, Mar 6)
Monday, March 3, 2014
Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical TrialsMarketwired( (Mon, Mar 3)
Wednesday, February 26, 2014
Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.PR Newswire( (Wed, Feb 26)
Monday, February 24, 2014
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli LillyMarketwired( (Mon, Feb 24)
Friday, February 21, 2014
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical TrialsMarketwired( (Fri, Feb 21)
finance.yahoo.com/q/h?s=NVLX+Headlines
pennystockdivas.com/
Follow on Twitter: twitter.com/PennyStockDivas
Follow on facebook: www.facebook.com/pennystock.divas?fref=ts
Like her facebook page:
www.facebook.com/pages/Penny-Stock-Divas/185908631442850?ref=hl
Read More: stockpycks.com/thread/590/psd-nvlx-biotech-monday-alert
Disclaimer: pennystockdivas.com is wholly owned by Global Innovator Relations LLC. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Global Innovator Relations, LLC and pennystockdivas.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at pennystockdivas.com/disclaimer.php Release of Liability: Through use of this website/newsletter viewing or using you agree to hold pennystockdivas.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Pennystockdivas.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Pennystockdivas.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and pennystockdivas.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Pennystockdivas.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Pennystockdivas.com has not been compensated for this release, but has previously been compensated $1500 cash by a non controlling third party for the release of this newsletter . Pennystockdivas.com, Global Innovator Relations, LLC nor any of its affiliates are not registered investment advisors or broker dealers.